Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1017 • ACR Convergence 2023
Cross Country Differences in b/tsDMARD Prescription Behavior: Associations Between Socioeconomics, Real World b/tsDMARD Use and Disease Outcomes
Isabell Nevins¹, Delphine COURVOISIER², Axel Finckh³, Ruth Fritsch-Stork⁴, Dan Nordstrom⁵, Ana Maria Rodrigues⁶, Stefan Dinescu⁷, Alvaro Garcia⁸, Mert Oztas⁹, Ziga Rotar¹⁰, Karen Salomon¹¹, Arvind Chopra¹², David Vega Morales¹³, Marieke De Buck¹⁴, Denis Choquette¹⁵, Richard Conway¹⁶, Florenzo Iannone¹⁷, CF Allaart¹⁸, Thomas Huizinga¹⁸, Kim Lauper¹⁹ and Sytske Anne Bergstra¹⁸, ¹Leiden University Medical Center, Amsterdam, Netherlands, ²Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ³HUG, Geneva, Switzerland, ⁴Medical Health center Mariahilf and Sigmund Freud Private University, Utrecht, Netherlands, ⁵Helsinki University Hospital, Helsinki, Finland, ⁶Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ⁷University of Medicine and Pharmacy of Craiova, Craiova, Romania, ⁸University Hospital del Tajo, Madrid, Spain, ⁹Istanbul University-Cerrahpasa, Istanbul, Turkey, ¹⁰University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹¹University of Massachusetts Medical School, Shrewsbury, MA, ¹²Center for Rheumatic Diseases, Pune, India, ¹³ROCHE, Ciudad de México, Mexico, ¹⁴Haaglanden Medisch Centrum, Den Haag, Netherlands, ¹⁵Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ¹⁶Trinity College Dublin, Dublin, Ireland, ¹⁷Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁸Leiden University Medical Center, Leiden, Netherlands, ¹⁹Geneva University Hospitals, Genève, Switzerland
Background/Purpose: The development of biologic and targeted synthetic (b/ts)DMARDs contributed to improved treatment outcomes in rheumatoid arthritis (RA). However, high medication costs may limit their…
Abstract Number: 1258 • ACR Convergence 2023
“What Is My Risk Really?”: A Qualitative Exploration and Ideal-Type Analysis of Preventive Interventions Among Individuals at Risk of Rheumatoid Arthritis
Lara S Chapman¹, Heidi J Siddle¹, Stefan Serban², Kulveer Mankia¹, Christopher Rooney³, Zhain Mustufvi⁴, Simon Pini⁵ and Karen Vinall-Collier⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Public Health Directorate, NHS England North West Region, Manchester, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴School of Dentistry, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom
Background/Purpose: A preclinical phase of rheumatoid arthritis (RA), in which ‘at-risk’ individuals develop autoantibodies and/or symptoms and progress to clinical arthritis and classifiable RA, is…
Abstract Number: 1277 • ACR Convergence 2023
Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study
Kenichiro Tokunaga¹, Takahiro Nishino², Hideto Oshikawa¹, Toshihiro Matsui³ and Shigeto Tohma⁴, ¹Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan, ³NHO Sagamihara National Hospital, Kanagawa, Japan, ⁴NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: This clinical study aimed to investigate the relationship between affected joints and the quality of life (QOL) in patients with rheumatoid arthritis (RA) in…
Abstract Number: 1293 • ACR Convergence 2023
Single Camera Hand Motion Capturing as a Digital Biomarker for Disease Activity in Rheumatoid Arthritis Using Computer Vision: The Proof-of-Concept MeFisto Study
Vincenzo Venerito¹, Tobias Maningold², Deborah Markham³, Marc Blanchard⁴, Florenzo Iannone¹ and Thomas Hügle⁵, ¹Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²Department of Rheumatology, University Hospital Bern (Inselspital), University Bern, Bern, Switzerland, ³on behalf of Department Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁴Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ⁵Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: Computer vision technology offerspromising possibilities for remotely assessing disease activity in rheumatoid arthritis (RA) patients, enabling telemedicine and improving access to care. The objective…
Abstract Number: 1309 • ACR Convergence 2023
Refractory RA Patients for Targeted Therapies in Real Life
Elena Grau Garcia¹, Laura Mas Sanchez², Pablo Francisco Muñoz Martínez³, Carmen Riesco Barcena¹, Alba Maria Torrat Noves¹, Daniel Ramos Castro¹, Anderson Victor Huaylla Quispe¹, Iago Alcantara Alvarez¹, Belen Villanueva Mañez¹, Ernesto Tovar Sugrañes¹, Elvira Vicens Bernabeu¹, Hikmat Charia¹, Marta De la Rubia Navarro², Luis Gonzalez Puig¹, Jose Ivorra Cortes¹, Samuel Leal Rodriguez¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Ines Canovas Olmos¹, Carmen Najera Herranz¹ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valéncia, Spain, ³Rheumatology Department. HUP La Fe, Sagunto, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Despite the increasing number of available targeted therapies (TT) in rheumatoid arthritis (RA), a proportion of RA patients fail to respond to their first…
Abstract Number: 1326 • ACR Convergence 2023
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 from the SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Koji Kato², Boulos Haraoui³, Maureen Rischmueller⁴, Yanxi Liu², Nasser Khan⁵, Heidi Camp² and Ricardo Xavier⁶, ¹Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ²AbbVie, Inc., North Chicago, IL, ³Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁴The Queen Elizabeth Hospital and Basil Hetzel Institute; Adelaide Medical School, University of Adelaide, Adelaide, Australia, ⁵Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: To evaluate the long-term safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, through week 204 in patients with RA from the long-term…
Abstract Number: 1342 • ACR Convergence 2023
The Delivery of the Super-repressor IκBα by Exosomes Has the Potential to Alleviate Inflammation Associated with Rheumatoid Arthritis
Ki-Jeong Park¹, Ji-Hyoun Kang¹, Hae-In Lee², Yu Jeong Lee¹, Moon-Ju Kim¹, So-Hee Ahn³, Jae-Kwang Yoo³, Chulhee Choi³ and Tae-jong Kim⁴, ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University, Gwangju, South Korea, ³ILIAS Biologics, Daejeon, South Korea, ⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is a persistent inflammatory disease primarily affecting the diarthrodial joints. Nuclear factor-κB (NF-κB) is a family of inducible transcription factors responsible…
Abstract Number: 1631 • ACR Convergence 2023
Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis
Chloe Peyton¹, Tate Johnson¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, Michael Duryee¹, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls³ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) predisposes affected individuals to develop multiple chronic conditions (i.e., multimorbidity). Mechanisms underlying multimorbidity onset in RA are incompletely understood, particularly for…
Abstract Number: 1727 • ACR Convergence 2023
Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice
Sheri Saunders, Garth Blackler, Patti Kiser, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada
Background/Purpose: Most rheumatoid arthritis (RA) patients express autoantibodies to post-translationally modified antigens, including citrullinated and homocitrullinated (also known as carbamylated) peptides. Homocitrulline and citrulline are…
Abstract Number: 1743 • ACR Convergence 2023
Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies
Lyndsey Cole¹, Sucai Liu², Brendan Allen², Marie Feser³, Kristen Demoruelle³, kevin Deane³, Michael Holer³ and kristine Kuhn², ¹University of Colorado School of Medicine, Centennial, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Our prior investigation identified a specific strain of Subdoligranulum didolesgii, S. dido7, to which dual IgA/IgG family plasmablast-derived monoclonal autoantibodies from individuals at-risk for…
Abstract Number: 1759 • ACR Convergence 2023
Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis
Christopher Mahony¹, Samuel Kemble², Paulynn Chin¹, Cesar Prada³, Annie Hackland¹, Patricia Reis-Nisa¹, Lucy-Jayne Marsh¹, Peter Keane¹, Constanze Bonifer¹, Christopher Buckley⁴, Stevephen Sansom⁵, Mark Coles⁴ and Adam Croft¹, ¹University of Birmingham, Birmingham, United Kingdom, ²University Birmingham, Rugeley, United Kingdom, ³The Kennedy Institute, Oxford, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵Kennedy Institute of Rheumatology, Oxford, United Kingdom
Background/Purpose: Fibroblasts are key effector cells in rheumatoid arthritis (RA) underpinning joint inflammation and damage. Synovial tissue fibroblasts are heterogenous and acquire pathogenic cell states…
Abstract Number: 1775 • ACR Convergence 2023
The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline
Jack Mordeson¹, Nozima Aripova¹, Michael Duryee¹, James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted R Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90%…
Abstract Number: 1904 • ACR Convergence 2023
Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs
Douglas White¹, Maya Buch², Suzanne Murray³, Diane Caballero⁴, Orsolya Nagy⁵ and Tsutomu Takeuchi⁶, ¹Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ³AXDEV Group Inc, Brossard, QC, Canada, ⁴AbbVie, Inc., Chicago, IL, ⁵AbbVie, Inc., Budapest, Hungary, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan
Background/Purpose: Treat-to-target (T2T) is a widely established and accepted approach in RA management, but its real-world implementation is suboptimal1. Further primary research is required to…
Abstract Number: 2096 • ACR Convergence 2023
Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure
Elizabeth Park¹, Kazato Ito², Christopher Depender¹, Jon Giles³ and Joan Bathon³, ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Columbia University, New York, NY
Background/Purpose: Elevated left ventricular (LV) mass (LVM) is an important precursor to clinical heart failure (HF) in the general population. In fact, rheumatoid arthritis (RA)…
Abstract Number: 2113 • ACR Convergence 2023
Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies
Grace Wright¹, Eduardo Mysler², Kevin Roberts³, Lindsay Sweet⁴ and Ahmed Shelbaya⁵, ¹Grace C Wright MD PC, New York, NY, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³Pfizer Inc., Cambridge, MA, ⁴Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., New York, NY
Background/Purpose: Sociodemographic factors can impact treatment response and safety outcomes in patients (pts) with RA. Here, we explore the impact of sociodemographic index (SDI) on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].